Daré Bioscience (NASDAQ:DARE) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why

Daré Bioscience, Inc. (NASDAQ:DARE) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.36 and traded as low as $3.02. Daré Bioscience shares last traded at $3.03, with a volume of 18,994 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The business has a 50-day simple moving average of $3.18 and a two-hundred day simple moving average of $3.35. The company has a market capitalization of $25.67 million, a price-to-earnings ratio of -4.99 and a beta of 1.38.

Institutional Trading of Daré Bioscience

A number of hedge funds have recently added to or reduced their stakes in the stock. AMH Equity Ltd lifted its position in Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 50,000 shares during the period. Geode Capital Management LLC lifted its position in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 3,593 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Daré Bioscience in the 4th quarter valued at approximately $52,000. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.